| Brambles Limited (BXB) ORDINARY FULLY PAID |
Industrials |
$22,112 |
Notification of cessation of securities - BXB
|
20 Mar 2026 8:36AM |
$22.430 |
$16.450 |
fallen by
26.66%
|
|
| Ventia Services Group Limited (VNT) ORDINARY FULLY PAID |
Industrials |
$5,137 |
Update - Notification of buy-back - VNT
|
20 Mar 2026 8:36AM |
$5.710 |
$6.270 |
risen by
9.81%
|
|
| Premier Investments Limited (PMV) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,025 |
Dividend/Distribution - PMV
|
20 Mar 2026 8:36AM |
$12.520 |
$12.680 |
risen by
1.28%
|
|
| SPDR S&P 500 ETF Trust (SPY) |
Financials |
$414 |
Distribution Rate Announcement
|
20 Mar 2026 8:35AM |
$939.900 |
$1,059.940 |
risen by
12.77%
|
|
| Aguia Resources Limited (AGR) ORDINARY FULLY PAID |
Materials |
$42 |
Receipt Of Final Proceeds From Sale Of Non-Core Asset
|
20 Mar 2026 8:34AM |
$0.020 |
$0.019 |
fallen by
5%
|
|
AGR - Price-sensitive ASX Announcement
Full Release
Key Points
- Aguia Resources Limited received C$1 million from the sale of Atocha Silver Project.
- The transaction ensures immediate financial certainty over potential future gains.
- Aguia emphasizes reallocating resources towards near-term production projects.
- The sale is part of a broader strategy to enhance portfolio value.
- The company operates mainly in Brazil and Colombia in phosphate and gold projects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Premier Investments Limited (PMV) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,025 |
Appendix 4D 1H26 Half Yearly accounts
|
20 Mar 2026 8:34AM |
$12.520 |
$12.680 |
risen by
1.28%
|
|
PMV - Price-sensitive ASX Announcement
Full Release
Key Points
- Net profit for the period attributable to owners was $101,694,000.
- Total comprehensive income was $97,847,000.
- Foreign currency translation losses impacted other comprehensive income.
- The company reported strong operating cash flows.
- Investments in associates contributed positively to earnings.
- Cash and cash equivalents at the end of the period were $360,061,000.
- The report details both continuing and discontinued operations.
- Equity dividends and lease liabilities were significant factors in cash flows.
- The financial report adheres to AASB 134 Interim Financial Reporting standards.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alliance Aviation Services Limited (AQZ) ORDINARY FULLY PAID |
Industrials |
$86 |
Change in substantial holding
|
20 Mar 2026 8:33AM |
$0.570 |
$0.535 |
fallen by
6.14%
|
|
| IPH Limited (IPH) ORDINARY FULLY PAID |
Industrials |
$995 |
Update - Notification of buy-back - IPH
|
20 Mar 2026 8:32AM |
$3.310 |
$3.870 |
risen by
16.92%
|
|
| Memphasys Limited (MEM) ORDINARY FULLY PAID |
Health Care |
$17 |
MENA Orders Secured, Expanded & Operations Unaffected
|
20 Mar 2026 8:30AM |
$0.005 |
$0.006 |
risen by
20%
|
|
MEM - Price-sensitive ASX Announcement
Full Release
Key Points
- Memphasys maintains uninterrupted Middle East operations despite regional conflict.
- New commercial orders secured from the UAE and Iraq.
- Egypt reseller partnership confirmed and progressing through regulatory approval.
- Turkey advancing through regulatory approvals with initial commercial orders anticipated.
- Memphasys and ITL aligned on flexible supply chain logistics.
- Ongoing demand and order activity consistent with company expectations.
- Qatar operations fully operational with continued use of Felixâ„¢ System by Hamad Medical Corporation.
- Memphasys’ strategy focuses on direct clinic engagement and diversified customer base.
- Resilience of demand in IVF sector supports broader commercial expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$453 |
Chair Letter to Shareholders
|
20 Mar 2026 8:30AM |
$9.470 |
$8.990 |
fallen by
5.07%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- CLINUVEL Pharmaceuticals Limited experienced its strongest financial half-year in history.
- The company's cash reserves reached A$233 million as of December 31.
- CLINUVEL's Board decided to continue with Philippe Wolgen as CEO to ensure stability and leadership continuity.
- The vitiligo program is a priority, with ongoing interactions with global regulators and the planned start of the CUV107 study.
- The Nasdaq listing process for a Level II ADR is underway, reflecting growing U.S. investor interest.
- The company faces risks related to regulatory approval in vitiligo and pipeline product commercialization.
- Commercial programs in erythropoietic protoporphyria (EPP) are prioritized as they fuel the company's financial sustainability.
- The Chair highlighted the importance of breaking through perceived market growth ceilings for the company's share price.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| National Australia Bank Limited (NAB) ORDINARY FULLY PAID |
Financials |
$112,827 |
Redemption Notice and Letter to NAB Capital Notes 3 holders
|
20 Mar 2026 8:30AM |
$46.620 |
$36.780 |
fallen by
21.11%
|
|
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$2,776 |
Net Tangible Asset Backing
|
20 Mar 2026 8:28AM |
$3.780 |
$4.380 |
risen by
15.87%
|
|
| Kogan.com Ltd (KGN) ORDINARY FULLY PAID |
Consumer Discretionary |
$393 |
Update - Notification of buy-back - KGN
|
20 Mar 2026 8:28AM |
$3.640 |
$4.115 |
risen by
13.05%
|
|
| Nova Minerals Limited (NVA) ORDINARY FULLY PAID |
Materials |
$350 |
Nova CEO to Present at the Emerging Growth Conference
|
20 Mar 2026 8:23AM |
$0.680 |
$0.765 |
risen by
12.50%
|
|
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$4,310 |
Notification regarding unquoted securities - TLX
|
20 Mar 2026 8:23AM |
$12.410 |
$12.700 |
risen by
2.34%
|
|
| Viva Leisure Limited (VVA) ORDINARY FULLY PAID |
Consumer Discretionary |
$150 |
Update - Notification of buy-back - VVA
|
20 Mar 2026 8:23AM |
$1.585 |
$1.525 |
fallen by
3.79%
|
|
| EDU Holdings Limited (EDU) ORDINARY FULLY PAID |
Consumer Discretionary |
$125 |
Update - Notification of buy-back - EDU
|
20 Mar 2026 8:22AM |
$0.610 |
$0.990 |
risen by
62.30%
|
|
| Ansell Limited (ANN) ORDINARY FULLY PAID |
Health Care |
$3,866 |
Update - Notification of buy-back - ANN
|
20 Mar 2026 8:22AM |
$28.630 |
$27.460 |
fallen by
4.09%
|
|
| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$415 |
Update - Notification of buy-back - RG8
|
20 Mar 2026 8:22AM |
$2.600 |
$2.890 |
risen by
11.15%
|
|
| Oohmedia Limited (OML) ORDINARY FULLY PAID |
Communication Services |
$646 |
Update - Notification of buy-back - OML
|
20 Mar 2026 8:22AM |
$0.935 |
$1.223 |
risen by
30.75%
|
|
| Vita Life Sciences Limited (VLS) ORDINARY FULLY PAID |
Health Care |
$133 |
Update - Notification of buy-back - VLS
|
20 Mar 2026 8:22AM |
$2.500 |
$2.450 |
fallen by
2%
|
|
| Peoplein Limited (PPE) ORDINARY FULLY PAID |
Industrials |
$70 |
Update - Notification of buy-back - PPE
|
20 Mar 2026 8:22AM |
$0.630 |
$0.640 |
risen by
1.59%
|
|
| Alcoa Corporation (AAI) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$29,994 |
Annual Report to Shareholders
|
20 Mar 2026 8:22AM |
$89.450 |
$113.670 |
risen by
27.08%
|
|
| FSA Group Limited (FSA) ORDINARY FULLY PAID |
Financials |
$158 |
Update - Notification of buy-back - FSA
|
20 Mar 2026 8:22AM |
$1.190 |
$1.260 |
risen by
5.88%
|
|
| Alcoa Corporation (AAI) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$29,994 |
Schedule 14A Additional Definitive Proxy Materials
|
20 Mar 2026 8:22AM |
$89.450 |
$113.670 |
risen by
27.08%
|
|